IC
KRRO icon

Ikarian Capital’s Korro Bio KRRO Stock Holding History

Ikarian Capital’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,016
Closed -$1M – 242
2021
Q2 		$1M Hold
2,016
– – 0.08% 160
2021
Q1 		$958K Buy
2,016
+298
+17% +$579K 0.03% 237
2020
Q4 		$3.03M Buy
+1,718
New +$2.27M 0.13% 130

Other funds holding KRRO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's KRRO Position: Q3 2021 in Review

Ikarian Capital sold out of Korro Bio (KRRO) in Q3 2021, closing a stake of 1,398 shares — an estimated $696K sold.

Ikarian Capital first reported a position in KRRO in Q1 2021 and held it in 2 quarters. The position peaked at $696K in Q2 2021. 88 funds tracked by Wall St. Rank hold KRRO as of Q3 2021.

  • Ikarian Capital reported no remaining Korro Bio position as of Q3 2021 after selling out during the quarter.
  • Ikarian Capital sold 1,398 Korro Bio shares in Q3 2021, an estimated $696K.
  • Ikarian Capital first reported a position in Korro Bio in Q1 2021 and held it in 2 quarters.
  • Ikarian Capital's Korro Bio position peaked at $696K in Q2 2021.
  • 88 funds tracked by Wall St. Rank held Korro Bio as of Q3 2021.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.